Abiraterone acetate can cause adverse reactions related both to its intended hormonal effect and to changes in steroid hormone production.
Important adverse effects
| Adverse effect | Why it matters |
|---|---|
| Hypertension | May become clinically significant |
| Hypokalemia | Low potassium can increase cardiac risk |
| Fluid retention | Can worsen edema or cardiovascular problems |
| Hepatotoxicity | Liver injury can be severe |
| Adrenocortical insufficiency | May occur particularly in certain treatment circumstances |
| Cardiovascular reactions | Requires attention in patients with cardiovascular disease |
| Fractures | Risk has been identified in certain treatment combinations |
Current labeling specifically warns about mineralocorticoid excess, adrenocortical insufficiency and hepatotoxicity.
Laboratory abnormalities
Reported laboratory abnormalities can include anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia and hypokalemia.
Warning signs
Prompt medical assessment may be needed for severe swelling, shortness of breath, chest symptoms, fainting, significant weakness, jaundice, dark urine, severe abdominal symptoms, confusion or other potentially serious symptoms.
Monitoring
Monitoring commonly includes blood pressure, serum potassium, fluid-retention symptoms and liver-function tests. The exact monitoring schedule depends on treatment context and prescribing information.